Maurizio Scaltriti: What stands out at ESMO23 is the critical role that innovative trial design, early mechanistic studies and ongoing translational analysis play in informing treatment strategy

Maurizio Scaltriti, Vice President of Translational Medicine at AstraZenica, shared a post on LinkedIn:

“It’s great to be back at ESMO this year! Looking at the presentations across the board, what stands out is the critical role that innovative trial design, early mechanistic studies and ongoing translational analysis play in informing treatment strategy.

For example, paired pre- and post-treatment biopsies tell us about potential mechanisms of resistance and help select the patients most likely to benefit from combinations, whereas longitudinal ctDNA assessment during dose escalation/expansion helps us monitor treatment response as it happens. By interrogating tumor biology in this way, we also continue to improve our understanding of drug mechanisms of action, which is valuable in making clinical decisions.

At AstraZeneca we use next generation diagnostics, such as ctDNA, computational pathology and multi-omics to monitor biomarkers of response and enhance our ability to select patients for personalized treatment. We do this to ensure that patients with cancer receive the right treatment at the right time, which is critical for improving outcomes. Read more about how we are using ctDNA in our trials.”

For more information click here.
Source: Maurizio Scaltriti/LinkedIn.